VIIBRYD Drug Patent Profile
✉ Email this page to a colleague
When do Viibryd patents expire, and when can generic versions of Viibryd launch?
Viibryd is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Viibryd
A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30th, 2019.
Summary for VIIBRYD
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 85 |
| Clinical Trials: | 16 |
| Patent Applications: | 123 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIIBRYD |
| Drug Sales Revenues: | Drug sales revenues for VIIBRYD |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
| What excipients (inactive ingredients) are in VIIBRYD? | VIIBRYD excipients list |
| DailyMed Link: | VIIBRYD at DailyMed |
Recent Clinical Trials for VIIBRYD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Forest Laboratories | Phase 1 |
| New York State Psychiatric Institute | Phase 4 |
| Forest Laboratories | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for VIIBRYD
Paragraph IV (Patent) Challenges for VIIBRYD
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VIIBRYD | Tablets | vilazodone hydrochloride | 10 mg, 20 mg, and 40 mg | 022567 | 5 | 2015-01-21 |
US Patents and Regulatory Information for VIIBRYD
VIIBRYD is protected by zero US patents and two FDA Regulatory Exclusivities.
FDA Regulatory Exclusivity protecting VIIBRYD
INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
Exclusivity Expiration: ⤷ Try a Trial
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIIBRYD
See the table below for patents covering VIIBRYD around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 1397357 | ⤷ Try a Trial | |
| Canada | 2782761 | ⤷ Try a Trial | |
| Canada | 2782791 | ⤷ Try a Trial | |
| Canada | 2782628 | ⤷ Try a Trial | |
| Canada | 2782857 | ⤷ Try a Trial | |
| Canada | 2782868 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
